Shopping Cart 0
Cart Subtotal
USD 0

Trillium Therapeutics Inc (TRIL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Trillium Therapeutics Inc (Trillium), formerly Neurogenesis Biotech Corp, is a clinical stage immuno-oncology company, which develops novel therapies for the treatment of cancer. The company's lead program, TTI-621, a SIRPaFc fusion protein is being developed for hematological malignancies. Its second SIRPaFc fusion protein, TTI-622, is primarily being developed for combination therapy. Trillium has developed a proprietary medicinal chemistry platform that is used for the creation of new chemical entities with improved pharmacological properties from validated drugs and drug candidates. The company utilizing this platform is also developing bromodomain inhibitor and epidermal growth factor receptor antagonist. Trillium is headquartered in Mississauga, Ontario, Canada.

Trillium Therapeutics Inc (TRIL)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Trillium Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Trillium Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Fluorinov Pharma Raises USD 1.5 Million In Venture Financing 12

Merger 13

Stem Cell Therapeutics Completes Merger With Trillium Therapeutics 13

Licensing Agreements 14

Trillium Therapeutics Amends Licensing Agreement with University Health Network 14

Stem Cell Therapeutics Enters Into Licensing Agreement With MaRS Innovation For Cancer Stem Cell Program 16

StemCell Technologies Enters Into Licensing Agreement With HUB Foundation for Organoid Technology 18

Stem Cell Therapeutics Enters Into Option For Licensing Agreement With University Of Toronto 19

Stem Cell Therapeutics Enters Into Option For Licensing Agreement With University of York For Prostate Cancer Stem Cell Assets 21

StemCell Technologies Enters Into Licensing Agreement With iPS Academia Japan For Induced Pluripotent Stem Cell Technologies 22

Equity Offering 23

Trillium Therapeutics Files Shelf Prospectus to Raise up to USD150 Million 23

Trillium Therapeutics Raises USD20 Million in Private Placement of Shares 24

Trillium Therapeutics Completes Underwriters' Partial Exercise of Over-Allotment Option of Public Offering of Shares and Prefererd Shares for USD31 Million 25

Trillium Therapeutics Raises USD55.2 Million in Public Offering of Shares 27

Stem Cell Therapeutics Completes Private Placement Of Shares For USD 31 Million 28

Stem Cell Therapeutics Completes Public Offering Of Units For USD 3.2 Million 30

Acquisition 31

Trillium Therapeutics Acquires Fluorinov Pharma 31

Trillium Therapeutics Inc-Key Competitors 32

Trillium Therapeutics Inc-Key Employees 33

Trillium Therapeutics Inc-Locations And Subsidiaries 34

Head Office 34

Other Locations & Subsidiaries 34

Recent Developments 35

Financial Announcements 35

Aug 08, 2018: Trillium Therapeutics reports second quarter 2018 financial and operating results 35

May 11, 2018: Trillium Therapeutics Reports First Quarter 2018 Financial and Operating Results 36

Mar 09, 2018: Trillium Therapeutics Reports Annual 2017 Financial And Operating Results 37

Nov 10, 2017: Trillium Therapeutics Reports Third Quarter 2017 Financial and Operating Results 38

Aug 11, 2017: Trillium Therapeutics Reports Second Quarter 2017 Financial and Operating Results 39

May 12, 2017: Trillium Reports First Quarter 2017 Financial and Operating Results 40

Mar 10, 2017: Trillium Therapeutics Reports Annual 2016 Financial and Operating Results 41

Corporate Communications 42

Jun 07, 2018: Trillium Therapeutics Appoints Yaping Shou, MD, PhD as Chief Medical Officer 42

Product News 43

07/05/2017: Trillium Provides Update on TTI-2341 EGFR Inhibitor Program 43

04/10/2018: Trillium Therapeutics Provides Update on TTI-622 Program 44

Clinical Trials 45

Nov 20, 2017: Trillium Therapeutics TTI-2341 EGFR Inhibitor Program Featured at the Society for Neuro-Oncology 22nd Annual Meeting 45

Feb 02, 2017: Trillium Therapeutics Provides Update On TTI-622 46

Appendix 47

Methodology 47

About GlobalData 47

Contact Us 47

Disclaimer 47


List Of Figure

List of Figures

Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Trillium Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Trillium Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Trillium Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Trillium Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Fluorinov Pharma Raises USD 1.5 Million In Venture Financing 12

Stem Cell Therapeutics Completes Merger With Trillium Therapeutics 13

Trillium Therapeutics Amends Licensing Agreement with University Health Network 14

Stem Cell Therapeutics Enters Into Licensing Agreement With MaRS Innovation For Cancer Stem Cell Program 16

StemCell Technologies Enters Into Licensing Agreement With HUB Foundation for Organoid Technology 18

Stem Cell Therapeutics Enters Into Option For Licensing Agreement With University Of Toronto 19

Stem Cell Therapeutics Enters Into Option For Licensing Agreement With University of York For Prostate Cancer Stem Cell Assets 21

StemCell Technologies Enters Into Licensing Agreement With iPS Academia Japan For Induced Pluripotent Stem Cell Technologies 22

Trillium Therapeutics Files Shelf Prospectus to Raise up to USD150 Million 23

Trillium Therapeutics Raises USD20 Million in Private Placement of Shares 24

Trillium Therapeutics Completes Underwriters' Partial Exercise of Over-Allotment Option of Public Offering of Shares and Prefererd Shares for USD31 Million 25

Trillium Therapeutics Raises USD55.2 Million in Public Offering of Shares 27

Stem Cell Therapeutics Completes Private Placement Of Shares For USD 31 Million 28

Stem Cell Therapeutics Completes Public Offering Of Units For USD 3.2 Million 30

Trillium Therapeutics Acquires Fluorinov Pharma 31

Trillium Therapeutics Inc, Key Competitors 32

Trillium Therapeutics Inc, Key Employees 33

Trillium Therapeutics Inc, Subsidiaries 34

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Trillium Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.